| The proto-oncogene ERG in megakaryoblastic leukemias. | leukemia, |
| Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. | prostate, |
| Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. | prostate, |
| ERG is a hematopoietic oncogene that may play a direct role in myeloid leukemia pathogenesis. | leukemia, |
| Results provide direct evidence for selective cooperating events in ERG-induced prostate tumorigenesis and offer a rational basis for combined therapeutic interventions against multiple oncogenic pathways in prostate cancer. | prostate, |
| ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. | prostate, |
| Results provide mechanistic insights to ERG oncogenesis in prostate cancer, involving activation of WNT signaling through FZD4, leading to cancer-promoting phenotypic effects, including EMT and loss of cell adhesion. | prostate, |
| FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. | prostate, |
| cortical cytoskeletal and extracellular matrix gene expression changes in prostate cancer are related to oncogenic ERG deregulation | prostate, |
| ERG oncogene modulates prostaglandin signaling in prostate cancer cells. | prostate, |
| Data indicate that ERG promotes proliferation of T-acute lymphoblastic leukemia (T-ALL) lymphoblasts; ERG promoter region (ERG +85 enhancer; sequence alignment given) is active in T-ALL lymphoblasts and is regulated by oncogenes (SCL, LYL1, LMO2). | leukemia, |
| Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. | prostate, |
| ERG oncoprotein overexpression in prostate cancer. Multiplex IHC adds to diagnostic prowess and efficiency of laboratory. | prostate, |
| The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer. | ovarian, |
| Clinical potential of the ERG oncoprotein in prostate cancer. | prostate, |
| Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer. | prostate, |
| Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. | prostate, |
| Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. | prostate, |
| Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. | prostate, |
| The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. | prostate, |